KORU Medical Systems (KRMD) Earnings Date & Reports

Key Takeaways

• KORU Medical Systems (KRMD) reports third quarter 2026 results on Tuesday, November 10, after the market close, with a conference call at 4:30 p.m. ET.
• Wall Street consensus calls for a net loss of about $0.02 per share on revenue of roughly $11.33 million, up about 8.9% year over year.
• KRMD has topped earnings per share (EPS) estimates in every quarter over the past two years, a rare consistency streak heading into this report.
• Second quarter 2026 showed momentum, with EPS of $0.01 beating the -$0.02 consensus and revenue of $12.05 million clearing the $11.62 million estimate.
• Investors will focus on subcutaneous infusion demand, gross margin, and any update to full-year guidance.
• For more on KRMD, visit Major News, Today's Price Move, Price Targets, and Forecast pages.
• Explore Trending AI Robots for automated, AI-driven trading strategies.

Earnings Context and Why It Matters

KORU Medical Systems is a medical technology company that develops, manufactures, and commercializes large-volume subcutaneous infusion solutions, including its FREEDOM Syringe Infusion System used for at-home drug delivery. This quarterly report matters because it offers a read on demand from both pharmaceutical partners and patients adopting subcutaneous therapies, a segment that has supported steady revenue growth. The company has also posted a long run of EPS beats, which has helped shape investor expectations. Coming off a stronger-than-expected second quarter, the third-quarter update will show whether that momentum is sustainable and whether management is on track to narrow losses toward profitability.

Earnings Expectations

Analysts expect KORU Medical to report a net loss of approximately $0.02 per share for the third quarter of 2026, the period ended September 30, 2026. The consensus revenue estimate stands at roughly $11.33 million, which would represent an increase of about 8.9% from the prior-year quarter.

Those expectations follow a strong second quarter, when the company posted EPS of $0.01 against a -$0.02 consensus and revenue of $12.05 million versus the $11.62 million estimate. Over the past two years, KRMD has exceeded EPS expectations 100% of the time and topped revenue estimates in most quarters. Key metrics to watch include gross margin, operating expense discipline, and any commentary on new customer activations or regulatory milestones tied to its infusion platform.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, and breakout candidates more efficiently than manual screening. For those tracking earnings-driven opportunities across the healthcare sector, the AI Screener offers a streamlined way to surface potential setups.

Market Reaction and Investor Sentiment

Sentiment heading into the print has been cautiously optimistic, reflecting KORU Medical's track record of exceeding EPS estimates and its recent revenue acceleration. The stock tends to be sensitive around earnings, with meaningful single-day moves following prior reports. Key risk factors include any miss on revenue growth, a wider-than-expected loss, or softer guidance, any of which could pressure shares given the company's still-negative earnings profile. Conversely, another beat combined with constructive commentary on the commercial pipeline could reinforce confidence in the path toward profitability. Investors will also weigh how the results compare with the company's own outlook and recent cost-reduction efforts.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should watch whether KORU Medical reaffirms or adjusts its full-year guidance, as any revision will set the tone for the remainder of 2026. Demand signals matter most: commentary on new pharmaceutical partnerships, customer adoption of large-volume subcutaneous infusion, and international expansion will indicate whether the recent revenue growth is durable.

Margin trends are another key area. The company has been working to improve gross margin and manage operating expenses, so any evidence of progress toward breakeven or reduced cash burn is likely to draw attention. Supply chain costs and pricing dynamics within its infusion product lines are also worth monitoring.

Finally, broader industry conditions in subcutaneous drug delivery and medical technology spending could influence near-term results. As more therapies shift toward at-home and self-administered delivery, KORU Medical's positioning in that market remains a central part of the long-term narrative, though execution against guidance will ultimately drive investor confidence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations